This study is designed to assess the safety, tolerability, efficacy and pharmacokinetics (PK)
of NS-089/NCNP-02 in subjects diagnosed with Duchenne muscular dystrophy (DMD), and to
determine the dosage for subsequent studies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Center of Neurology and Psychiatry, Japan